9342-8530 Quebec Inc DGCRF

Study on Value of Prostate Tests

[RetailRube]

Perhaps some of the recent weakness in CUR was caused by the article published yesterday in a Medical Journal, finding prostate cancer tests do not reduce deaths and so are of little value.  The study said that since the cancers are slow-growing, early detection does not help reduce death rates.  I read a report of the study on the Bloomberg news site, where it was in one of their top news items.  It seems to me this debate is an old one.  For an individual making the testing decision, the risk/reward ratio makes it a no-brainer to take the test.

I read the post which summarized the conference call.  There didn't seem to be any surprises.  Perhaps investors don't like the idea of waiting until the Feb 2011 conference for the next news.  So the hot money crowd is likely selling CUR to try riding something else, then return in January.